Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today

ARWR +23.34%

Key Points

• The biotech published its latest set of annual results.

• It's now got several revenue streams that are already significantly boosting the fundamentals.

• 10 stocks we like better than Arrowhead Pharmaceuticals ›

The stock of biotech Arrowhead Pharmaceuticals (NASDAQ: ARWR) experienced a serious Hump Day jump. On the Wednesday before Thanksgiving, the company's shares rose by more than 23%, thanks largely to its latest earnings release.

A flying arrow

The previous day at market close, Arrowhead took the wraps off its full-year, fiscal 2025 results. The company's revenue for the period exceeded $829 million, primarily driven by an influx of licensing and collaboration funds, which was significantly higher than the $3.6 million reported in 2024.

It also narrowed attributable net loss to $1.6 million, compared to the year-ago deficit of $599 million.

The most significant event for Arrowhead hasn't been its annual earnings release, though. Earlier this month, the U.S. Food and Drug Administration (FDA) approved its Redemplo for the treatment of adults with familial chylomicronemia syndrome (FCS). This is a rare genetic disorder that impairs the body's ability to metabolize fats. Redemplo is Arrowhead's first FDA nod.

Coming soon to a pharmacy near you

These are exciting and memorable times for Arrowhead, which is in front of adding a new revenue stream with Redemplo. Meanwhile, its all-important collaborations are also bringing in funds, and should continue to do so as it gears up for commercializing the new drug. This is a company on the move, and therefore a stock for investors to watch -- especially biotech aficionados.

Should you buy stock in Arrowhead Pharmaceuticals right now?

Before you buy stock in Arrowhead Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arrowhead Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $563,022!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,090,012!*

Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 24, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today was originally published by The Motley Fool